Mayne shares fire up after announcing promotion of Fabior & Sorilux
Published 11-JAN-2017 15:15 P.M.
|
3 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Shares in Mayne Pharma Group (ASX: MYX) hit a high of $1.36 in the first hour of trading on Wednesday, representing an increase of 3% compared with the previous day’s close of $1.32.
This is a good performance on a day in which the Healthcare sector is relatively flat and all the focus tends to be on the mining sector with the S&P/ASX 200 Materials index up 2.4%.
However before we go further, it should be noted that broker projections and price targets are only estimates and may not be met. Also, historical data in terms of earnings performance and/or share trading patterns should not be used as the basis for an investment as they may or may not be replicated. Those considering this stock should seek independent financial advice.
The new products, Fabior and Sorilux, will be promoted in the United States by Mayne’s Specialty Brands division. Importantly, they are complementary to the company’s high profile dermatology product, Doryx, the first branded product launched by the group’s Specialty Brands division in the US in May 2015.
Mayne has been one of only a handful of stocks in the S&P/ASX 200 (XJO) to perform poorly in the last three months as the market boomed in the ASX 200 increased circa 800 points since early November.
Mayne’s share price has declined from circa $2.00 in October to hit a low of $1.20 in mid-December before recovering to its current level, but it has substantially underperformed the S&P/ASX 200 Healthcare index over the last three months.
However, Bell Potter likes the stock, and after running the ruler across it on December 19 the broker maintained its buy recommendation and 12 month price target of $1.83, implying upside of approximately 35% to its current trading range.
Strategic fit
Harking back to today’s news, Mayne’s Chief Executive Scott Richards said, “Both products are a great strategic fit with the existing Doryx franchise, while being well differentiated with compelling clinical data that physicians and patients will appreciate”.
Sorilux is a patent protected foam product indicated for the topical treatment of plaque psoriasis of the scalp and body, a condition affecting up to 6 million Americans each year.
Fabior also has a large addressable market with the patent protected foam product indicated for the topical treatment of acne. The product is part of the single active retinoid market in which 5 million prescriptions are written each year. Furthermore, acne is the most prevalent skin disease in the US, affecting as many as 50 million people of all ages.
From an operational perspective, Richards highlighted the fact that the company has now internalised its 60 person dermatology sales team from a third-party contract sales organisation which should provide cost savings, assist in attracting and retaining talent, while also leading to improved performance management.
Looking to the future, Mayne expects to commercialise complementary product innovations in dermatology and other specialty therapeutic areas, utilising the company’s internal pipeline or via targeted in-licensing and/or product acquisitions.
General Information Only
This material has been prepared by Jason Price. Jason Price is an authorised representative (AR 000296877) of 62 Consulting Pty Limited (ABN 88 664 809 303) (AFSL 548573) (62C), and a Director of S3 Consortium Pty Ltd (trading as StocksDigital).
This material is general advice only and is not an offer for the purchase or sale of any financial product or service. The material is not intended to provide you with personal financial or tax advice and does not take into account your personal objectives, financial situation or needs. Although we believe that the material is correct, no warranty of accuracy, reliability or completeness is given, except for liability under statute which cannot be excluded. Please note that past performance may not be indicative of future performance and that no guarantee of performance, the return of capital or a particular rate of return is given by 62C, Jason Price, StocksDigital, any of their related body corporates or any other person. To the maximum extent possible, 62C, Jason Price, StocksDigital, their related body corporates or any other person do not accept any liability for any statement in this material.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.